Structure determination of MS-444; a new myosin light chain kinase inhibitor

Y Aotani1, Y Saitoh

  • 1Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Japan.

The Journal of Antibiotics
|September 1, 1995
PubMed

Insights

A new compound, MS-444, was identified as a myosin light chain kinase inhibitor. Its chemical structure was determined using spectral analysis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Natural Products

Background:

  • Myosin light chain kinase (MLCK) plays a crucial role in smooth muscle contraction.
  • Inhibitors of MLCK are potential therapeutic agents for various diseases.
  • Natural products offer a rich source of novel bioactive compounds.

Purpose of the Study:

  • To isolate and characterize a novel inhibitor of myosin light chain kinase.
  • To elucidate the chemical structure of the identified compound.

Main Methods:

  • Isolation of the compound from the culture broth of Micromonospora sp. KY7123.
  • Structure elucidation using comprehensive spectral analysis (e.g., NMR, Mass Spectrometry).

Main Results:

  • A novel compound, designated MS-444, was successfully isolated.
  • MS-444 was identified as a myosin light chain kinase inhibitor.
  • The chemical structure of MS-444 was determined to be 5,8-dihydroxy-3-methyl-(9H)-naphtho[2,3-c]furan-4-one.

Conclusions:

  • MS-444 is a novel myosin light chain kinase inhibitor derived from Micromonospora sp. KY7123.
  • The determined structure provides a basis for further investigation of its pharmacological properties and potential therapeutic applications.